DNM1L and pulmonary arterial hypertension: DRP1 inhibitor can inhibit the development of PAH by reversing mitochondrial function (Parra et al., 2017; Tian et al., 2018; Zhuan et al., 2020; Wu et al., 2021; Xiao et al., 2022).